JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

A Review on Renaissance of Targeted Covalent Inhibitors

Udaya Kumari Tula*[1], Sunitha Panthagada[2]

[1]*Research Scientist, DSK Biopharma Inc., Morrisville, North Carolina, USA*
[2]*Associate Professor, Department of Pharmaceutical Analysis, Koringa College of Pharmacy, Korangi, Tallarevu, Andhra Pradesh, India*

Publication history: Received on 2nd October 2025; Revised on 16th October 2025; Accepted on 20th October 2025

Article DOI: 10.69613/5t2w9v10

Abstract: Targeted Covalent Inhibitors (TCIs) have evolved from their historical classification as non-selective toxins to become a cornerstone of modern precision medicine. While early pharmaceutical strategies largely avoided covalent modalities due to apprehensions regarding idiosyncratic toxicity and haptenization, the clinical success of third-generation kinase inhibitors and KRAS G12C modulators has catalyzed a paradigm shift in rational drug design. This resurgence is not merely a return to reactive chemistry but represents a sophisticated evolution towards tunable reversibility and the engagement of "difficult" nucleophiles. The integration of structural biology with reactive group chemistry now permits the targeting of residues previously considered undruggable, such as lysine, tyrosine, and serine, thereby vastly expanding the ligandable proteome. Current research prioritizes the decoupling of biochemical potency from systemic exposure through the optimization of residence time and the "hit-and-run" pharmacological profile. Furthermore, the development of reversible covalent warheads utilizing cyanoacrylates and aldehydesoffers a strategic solution to the challenges of permanent protein modification, mitigating off-target risks while maintaining high affinity. This review discusses about the trajectory of warhead evolution, the kinetic principles governing specific inactivation efficiency (k_{inact}/K_I), and the structural activity relationships that facilitate the precise modification of non-catalytic residues. The strategic deployment of these advanced chemical tools enables the effective interrogation of biological targets that are resistant to traditional non-covalent inhibition.

Keywords: Targeted Covalent Inhibitors; Electrophiles; k_{inact}/K_I; SuFEx Chemistry; Residence Time.

1. Introduction

The historical trajectory of small-molecule drug discovery has been deeply entrenched in the reversible, non-covalent paradigm. This preference was largely driven by a pervasive dogma associating the covalent modification of host proteins with severe safety liabilities, particularly idiosyncratic drug reactions (IDRs) and immune-mediated hepatotoxicity. The underlying fear was that reactive species would indiscriminately haptenize endogenous proteins, triggering autoimmune responses [1]. As a result, for much of the late 20th century, electrophilic functional groups were systematically flagged as structural alerts or categorized alongside "PAINS" (Pan-Assay Interference Compounds), leading to their rigorous excision during the lead optimization phases to mitigate potential toxicity risks [2].

However, this conservative orthodoxy has been radically upended in the last decade, catalyzing a renaissance in the field following the regulatory approval and immense clinical efficacy of blockbuster targeted covalent inhibitors (TCIs) such as ibrutinib (targeting BTK), osimertinib (targeting EGFR), and sotorasib (targeting KRAS G12C). These pioneering agents have provided irrefutable clinical evidence that electrophiles, when rationally positioned and finely tuned for specific reactivity, can yield pharmacological profiles superior to those of traditional non-covalent binders. The distinct advantages of this modality include the achievement of near-complete and sustained target occupancy, a duration of action that is dictated by protein turnover rather than systemic pharmacokinetics (uncoupling PK/PD), and the critical capacity to effectively outcompete millimolar concentrations of endogenous substrates like ATP or GTP at the active site [3]. The contemporary landscape of TCIs represents a sophisticated evolution from the non-specific, highly reactive "suicide inhibitors" of the past. Modern TCI design is predicated on a stringent two-step recognition mechanism: an initial, high-affinity non-covalent binding event (K_I) that orients the electrophilic warhead in immediate proximity to a specific nucleophile, followed by a rapid, proximity-driven bond-forming reaction (k_{inact}). This requisite for precise molecular recognition prior to covalent bond formation confers an exceptional degree of kinetic selectivity, thereby significantly minimizing the risk of off-target alkylation events [4]. As the domain of covalent inhibition matures, research efforts have expanded beyond the traditional targeting of highly nucleophilic cysteine residues. The frontier of discovery now encompasses the interrogation of "harder" nucleophiles such as lysine, tyrosine, and serine, alongside the strategic implementation of reversible covalent chemistries to modulate residence time and optimize the therapeutic index [5].

* Corresponding author: Udaya Kumari Tula

2. Evolution of Warhead Chemistry

2.1. Covalent Pharmacology

The genesis of covalent pharmacology can be traced to early agents like aspirin and penicillin, which functioned through mechanism-based inactivation. These compounds were often discovered serendipitously rather than through rational design and were frequently termed "suicide inhibitors" because they utilized the enzyme's own catalytic machinery to activate a latent reactive group, resulting in irreversible inhibition [6]. While effective, this approach was strictly limited to enzymes with specific catalytic mechanisms capable of unmasking the inhibitor's reactivity. The transition to modern TCIs involves the intentional incorporation of reactive electrophiles (warheads) onto a scaffold that has been extensively optimized for non-covalent affinity. This separation of binding affinity from chemical reactivity allows for the targeting of non-catalytic nucleophiles, provided they are accessible within the binding pocket [7]. The design philosophy has thus shifted from maximizing intrinsic reactivity to optimizing the "reaction window," ensuring that the warhead is sufficiently inert in isolation to prevent systemic toxicity but highly reactive when driven by the local electrostatic environment of the protein active site [8].

2.2. The Warhead Toolbox

The diversity and chemical nature of the electrophilic toolbox directly determine the range of accessible biological targets. The physicochemical properties of the warhead dictate not only the reaction rate but also the selectivity profile, metabolic stability, and potential for off-target interactions of the inhibitor.

2.2.1. Acrylamides

α,β-unsaturated amides, or acrylamides, remain the most prevalent warheads in clinical candidates targeting cysteine. Functioning as Michael acceptors, these "soft" electrophiles react preferentially with "soft" nucleophiles like the thiolate anion of cysteine, adhering to the principles of Hard and Soft Acids and Bases (HSAB) theory [9]. The dominance of acrylamides stems from their relatively low intrinsic reactivity, which prevents non-specific reactions with circulating glutathione or plasma proteins, thereby enhancing their metabolic stability. Reactivity in these systems is typically largely driven by the proximity effect induced by the scaffold binding and, in some cases, by the specific geometry of the transition state stabilized by the protein environment [10]. Variations such as propargyl amides and vinyl sulfonamides allow for subtle tuning of electrophilicity and transition state geometry to match specific active site architectures, providing medicinal chemists with a spectrum of reactivity to optimize the specific inactivation rate [11].

Table 1. Comparative Analysis of Common Electrophilic Warheads

Warhead Class	Reactivity	Primary Target Residue	Reversibility	Mechanism
Acrylamides	Moderate (Michael Acceptor)	Cysteine (Thiol)	Irreversible	The "Gold Standard" for kinases; tunable via substitution (e.g., α-cyano).
Sulfonyl Fluorides	Context-Dependent	Tyrosine (Phenol), Lysine (ε-Amino)	Irreversible	Highly stable in water; requires specific protein environment for activation (SuFEx).
Vinyl Sulfones	Moderate to High	Cysteine, Lysine	Irreversible	Less specific than acrylamides; capable of targeting protonated lysines in specific pockets.
Cyanoacrylates	High (Reversible Michael Acceptor)	Cysteine	Reversible	Forms a labile bond allowing for tunable residence time; mitigates permanent off-target modification.
Epoxides	High (Strain-driven)	Cysteine, Histidine, Aspartate	Irreversible	Historically "suicide inhibitors"; less common in modern design due to promiscuity concerns.
Aldehydes/Ketones	Reversible Condensation	Cysteine, Serine, Lysine	Reversible	Forms hemiacetals/hemithioacetals/imines; often used for proteases and reversible covalent kinases.

2.2.2. Sulfonyl Fluorides

The renaissance of sulfur (VI) fluoride exchange (SuFEx) chemistry, championed by Sharpless and colleagues, has introduced sulfonyl fluorides as a privileged class of warheads for targeting residues beyond cysteine, particularly tyrosine and lysine [12]. Unlike highly reactive sulfonyl chlorides which are prone to rapid hydrolysis, sulfonyl fluorides are remarkably stable in aqueous environments and resist non-specific hydrolysis. Their unique reactivity profile is "context-dependent," meaning they require a specific protein microenvironmentoften involving hydrogen bonding interactions that activate the fluoride leaving group or stabilize the pentacoordinate transition stateto undergo nucleophilic substitution [13]. This context specificity makes them ideal probes for expanding the druggable proteome to include tyrosine and histidine residues, which were previously difficult to target selectively due to their lower nucleophilicity compared to cysteine [14].

2.2.3. Cyanoacrylates and Aldehydes

A significant limitation of irreversible inhibition is the potential for permanent modification of off-targets, which can lead to haptenization and subsequent immunogenicity. To mitigate this risk, reversible covalent inhibitors have emerged as a powerful alternative. These molecules utilize warheads such as cyanoacrylates, electron-deficient ketones, and aldehydes to form a covalent bond that is thermodynamically labile [15]. For instance, cyanoacrylates can form a covalent adduct with a cysteine residue that, unlike the stable thioether formed by simple acrylamides, exists in a rapid equilibrium with the unbound state. This strategy combines the high affinity of covalent bonding with the safety profile of reversible kinetics, allowing the inhibitor to dissociate from the target as drug concentration decreases, thereby reducing the duration of off-target engagement while maintaining efficacy at the primary target [16].

3. Mechanistic Design

3.1. Half-maximal inhibitory concentration

In the realm of covalent inhibition, the half-maximal inhibitory concentration (IC_{50}) is a time-dependent variable and thus an unreliable metric for potency. As the incubation time increases, the IC_{50} value of an irreversible inhibitor will decrease asymptotically towards the concentration of the enzyme, making comparisons between inhibitors difficult [17]. A more rigorous kinetic framework is required, described by the two-step mechanism:

$$E + I \overset{K_I}{\rightleftharpoons} E \cdot I \xrightarrow{k_{inact}} E - I$$

Here, K_I represents the non-covalent dissociation constant (affinity) of the initial encounter complex, and k_{inact} is the first-order rate constant for the bond formation step [18]. The ratio k_{inact}/K_I serves as the second-order rate constant describing the efficiency of covalent inactivation. Maximizing this efficiency does not necessarily require a highly reactive warhead (high k_{inact}); rather, a highly optimized non-covalent scaffold (low K_I) allows for the use of a less reactive ("tuned down") warhead. This balance is critical for selectivity: a "hot" electrophile with poor recognition will promiscuously alkylate off-targets, whereas a moderate electrophile with high affinity will only react when precisely positioned by the scaffold, ensuring that the bond formation is driven by local concentration rather than intrinsic reactivity [19].

Table 2. Kinetic Parameters Distinguishing Inhibition Modalities

Kinetic Parameter	Non-Covalent Inhibitor	Irreversible Covalent Inhibitor (TCI)	Reversible Covalent Inhibitor
Primary Metric	K_d (Dissociation Constant) or IC_{50}	(k_{inact}/K_I) (Inactivation Efficiency)	Residence Time (τ) & Occupancy
Time-Dependence	Time-independent equilibrium	Time-dependent (IC_{50}) decreases over time)	Time-dependent equilibrium
Off-Rate (k_{off})	Typically rapid	Effectively zero (infinite residence time)	Slow but finite (tunable)
Duration of Action	Driven by plasma half-life ($t_{1/2}$)	Driven by protein turnover rate (t_{sys})	Driven by dissociation rate (k_{off})
Target Saturation	Requires maintained systemic concentration	Can be maintained after systemic clearance ("Hit-and-Run")	Intermediate; sustains occupancy longer than non-covalent

3.2. Optimizing Residence Time and the "Hit-and-Run" Strategy

One of the primary advantages of irreversible inhibitors is the decoupling of pharmacodynamics from pharmacokinetics. Once the target is covalently modified, inhibition persists until the protein is turned over (resynthesized), regardless of the clearance of the free drug from systemic circulation [20]. This "hit-and-run" profile allows for shorter exposure times, potentially reducing toxicity associated with sustained plasma levels and minimizing the window for off-target interactions [21]. However, for targets with rapid turnover rates, the duration of effect may be limited by the synthesis of new protein. Conversely, for reversible covalent inhibitors, the residence time ($\tau = 1/k_{off}$) becomes the defining parameter. By engineering warheads that form slowly dissociating complexes, chemists can achieve prolonged target occupancy that is tunable, avoiding the permanent adducts that raise safety concerns while outperforming the residence times of purely non-covalent binders [22].



Figure 1. Kinetic Mechanisms of Covalent Inhibition

4. Targeting Non-Catalytic Residues

4.1. Strategies for Proteins Lacking Active Site Cysteine

The limitation of cysteine-targeted strategies is the low abundance of cysteine residues (approx. 2.3% of the proteome) and their infrequent occurrence in functional pockets. To address this, current TCI design focuses on residues with higher intrinsic pKa values or lower nucleophilicity.

Table 3. Emerging Trends for Targeting Non-Cysteine Residues

Target Residue	Intrinsic Challenges	Strategic Chemical Solution	Mechanism of Activation
Lysine (ε-NH_2)	Usually protonated (NH_3^+) at physiological pH; low nucleophilicity.	Sulfonyl Fluorides, Aryl Fluorosulfates, Vinyl Sulfones	pKa Perturbation: Targeting lysines in hydrophobic or distinct electrostatic pockets that depress pKa.
Tyrosine (Phenol)	Low nucleophilicity compared to Cys; sterically hindered.	SuFEx Chemistry (Sulfonyl Fluorides)	Proximity-Driven Exchange: Fluoride displacement facilitated by H-bonding networks in the active site.
Serine (Hydroxyl)	Poor nucleophile; generally requires catalytic activation.	Fluorophosphonates, Carbamates	Catalytic Trap: Often targets the catalytic triad of serine hydrolases; context-specific activation for non-catalytic sites.
Methionine (Thioether)	Weak nucleophile; rarely targeted.	Epoxides, Alkyl Halides (Specialized)	Exophilic Attack: Very rare; requires extremely high local concentration and specific geometry.

The local protein environment plays a pivotal role here; a lysine residue, typically protonated (ammonium form) at physiological pH, can have its pKa significantly perturbed by adjacent positive charges or hydrophobic pockets, rendering it nucleophilic enough to react [23]. Computational tools and pKa prediction algorithms are now integral to identifying these "reactive hotspots" on protein surfaces that were previously ignored [24].

4.2. Lysine Targeting: Vinyl Sulfones and Activated Esters

Lysine targeting requires electrophiles capable of reacting with the ε-amino group. While classic amine-reactive reagents (e.g., NHS-esters) are too non-selective for intracellular use, tuned warheads like vinyl sulfones and sulfonyl fluorides have shown promise. Vinyl sulfones, while less specific than acrylamides, can be optimized to react with lysine residues that are positioned to facilitate proton transfer. Recent advances have also employed aryl-fluorosulfates and specialized activated esters that exploit proximity-driven reactivity to selectively modify a specific lysine without labeling the abundant surface lysines typical of most proteins [25]. The development of these lysine-targeting warheads has been crucial for kinase inhibitors that target the conserved catalytic lysine in the ATP-binding pocket [26].

4.3. Tyrosine and Serine Targeting: Phosphorus-Based Electrophiles

Tyrosine and serine possess hydroxyl groups that are generally poor nucleophiles at neutral pH. However, new classes of phosphorus-based electrophiles and reactive fluorophosphonates have been developed to target catalytic serines (e.g., in serine hydrolases) and, more recently, non-catalytic tyrosines. The SuFEx methodology has been particularly instrumental here, enabling the targeting of tyrosine residues via sulfur-fluoride exchange, forming stable sulfonate linkages [27]. These approaches are expanding the scope of TCIs to protein families previously considered intractable to covalent intervention, such as phosphatases and difficult-to-drug transcription factors [28].



Figure 2. Flowchart for Rational Design Strategy for Targeting Non-Catalytic Residues

5. Case Studies in Structure-Activity Relationship (SAR)

5.1. KRAS G12C Inhibitors

The development of inhibitors for KRAS G12C represents the pinnacle of modern TCI design and a landmark achievement in oncology. For decades, RAS proteins were deemed "undruggable" due to their picomolar affinity for GTP, lack of deep hydrophobic pockets, and smooth surface topology [29]. The breakthrough came with the identification of a cryptic pocket (Switch II pocket) beneath the effector binding loop, present only in the GDP-bound state. Inhibitors like sotorasib (AMG 510) utilize an acrylamide warhead to covalently engage the mutant Cysteine 12 [30]. The positioning of the warhead is critical; it must trap the protein in the inactive GDP-bound conformation. This case study exemplifies the requirement for precise structural insights: the warhead does not merely block an active site but locks a dynamic protein into an inactive state via an allosteric covalent modification, preventing the nucleotide exchange required for signal transduction [31].

Table 4. Targeted Covalent Inhibitors in Clinical Oncology

Drug Name	Target	Warhead Chemistry	Target Residue	Mechanism/Indication
Ibrutinib	BTK	Acrylamide	Cys481	Irreversible inhibition of B-cell receptor signaling (CLL, MCL).
Osimertinib	EGFR (T790M)	Acrylamide	Cys797	Selective for mutant EGFR; spares wild-type EGFR to reduce toxicity (NSCLC).
Sotorasib (AMG 510)	KRAS G12C	Acrylamide	Cys12 (Mutant)	Traps KRAS in GDP-bound inactive state; targets cryptic Switch II pocket (NSCLC).
Neratinib	HER2/EGFR	4-(Dimethylamino)crotonamide	Cys773/Cys805	Pan-HER covalent inhibitor (Breast Cancer).
Fenebrutinib	BTK	Inverted Cyanoacrylamide	Cys481	Reversible covalent inhibitor designed to overcome resistance or tune selectivity.
Zanubrutinib	BTK	Acrylamide	Cys481	Second-generation TCI with improved selectivity over Ibrutinib.

5.2. BTK Inhibitors

Ibrutinib, the first-in-class Bruton's Tyrosine Kinase (BTK) inhibitor, targets Cysteine 481 via an acrylamide moiety. While highly effective in B-cell malignancies, acquired resistance frequently emerges through a C481S mutation, where the nucleophilic cysteine is replaced by a less reactive serine, rendering the covalent mechanism inert [32]. This challenge has driven the evolution of next-generation inhibitors. Reversible non-covalent inhibitors (e.g., fenebrutinib) were developed to bypass the requirement for C481. Furthermore, novel reversible covalent strategies are being explored that can interact with the serine residue or alternative nucleophiles within the pocket, illustrating how resistance mechanisms drive the cycle of warhead innovation [33]. These distinct generations of BTK inhibitors highlight the continuous interplay between clinical feedback and chemical refinement.



Figure 3. The Reactivity-Selectivity of TCI Design

6. Immunogenicity

The primary safety concern hindering the broader adoption of Targeted Covalent Inhibitors (TCIs) remains the potential for formation of covalent adducts with off-target proteins. This phenomenon can precipitate idiosyncratic drug reactions (IDRs), which are rare but severe adverse events typically observed only after a drug has entered widespread clinical use. The mechanistic basis for these reactions often involves the "hapten hypothesis," wherein the electrophilic drug or its reactive metabolite modifies a self-protein. This drug-protein conjugate is subsequently internalized and processed by antigen-presenting cells, leading to the presentation of modified peptides on Major Histocompatibility Complex (MHC) molecules. If these neo-epitopes are recognized

as foreign by T-cells, they can trigger a potent immune hypersensitivity reaction [34]. Consequently, distinguishing between specific target engagement and indiscriminate protein alkylation is the central challenge in TCI safety optimization.

Table 5. Safety Optimization for Covalent Drugs

Safety Challenge	Description	Mitigation Strategy	Chemical Approach
Idiosyncratic Toxicity (IDR)	Rare, unpredictable toxicity often linked to immune reaction.	Reactivity Tuning	Lowering intrinsic reactivity of the warhead so it only reacts in the specific protein environment ("Goldilocks" reactivity).
Haptenization	Drug-protein adducts presented as antigens, causing allergy.	Reversible Covalency	Using reversible warheads (e.g., cyanoacrylates) allows the adduct to dissociate before immune processing occurs.
Glutathione (GSH) Depletion	Rapid reaction with cellular GSH leading to oxidative stress.	Steric Shielding	Adding steric bulk near the electrophile to prevent attack by free GSH while allowing access to the target Cys.
Off-Target Promiscuity	Labeling of non-target proteins.	Scaffold Optimization	Maximizing non-covalent affinity (K_I) to drive selectivity; the warhead should be a "passenger," not the driver.

To minimize this risk, medicinal chemists employ "chemical strategies to minimize haptenization" that prioritize the decoupling of intrinsic chemical reactivity from specific biochemical potency. The objective is to tune the reactivity of the warhead so that it resides in a "Goldilocks zone"reactive enough to form a bond when positioned precisely next to the target nucleophile by the scaffold's binding affinity (proximity effect), yet insufficient to react with abundant housekeeping proteins (e.g., serum albumin) or cellular nucleophiles (e.g., glutathione) during systemic circulation. By optimizing the non-covalent binding constant (K_I) rather than increasing the reaction rate (k_{inact}), selectivity is driven by molecular recognition rather than raw electrophilicity [35].

Additionally, bioisosteric replacements for reactive groups are employed to alter the metabolic fate of the inhibitor and prevent the formation of "pro-haptens." Pro-haptens are chemically inert parent drugs that are metabolically activated into highly reactive species (e.g., quinone imines or epoxides) by cytochrome P450 enzymes. These reactive metabolites can indiscriminately modify hepatic proteins, leading to toxicity. Strategies such as blocking sites of metabolic oxidation with fluorine or replacing structural alerts with safer bioisosteres can prevent the formation of these toxic metabolites while maintaining the desired pharmacological activity on the target [36]. The emerging trend towards reversible covalent inhibitors also serves as a critical safety feature. Unlike irreversible inhibitors, which permanently modify off-targets, reversible TCIs form a chemical bond that has a finite lifetime. If an off-target reaction occurs, the labile nature of the bond allows the drug to dissociate from the protein before the adduct can be processed by the immune system. If the rate of dissociation (k_{off}) is faster than the rate of antigen processing and presentation, the immune system remains "blind" to the transient modification, effectively increasing the safety margin and reducing the risk of immunogenicity [37].

7. Conclusion

The renaissance of targeted covalent inhibitors is an important milestone in medicinal chemistry, transitioning from the avoidance of reactive intermediates to their strategic exploitation. The field has unlocked a vast array of therapeutic targets previously considered undruggable by moving beyond the simple "cysteine-trapping" paradigm. The integration of tunable reversibility, precise kinetic modeling using the k_{inact}/K_I parameter, and the expansion of the warhead toolbox to include SuFEx and phosphorus-based chemistries has fundamentally altered the landscape of drug discovery. Future research will likely focus on the hybridization of covalent warheads with other modalities, such as Proteolysis Targeting Chimeras (PROTACs), to combine covalent target engagement with induced protein degradation. The strategic design of TCIs will continue to offer potent solutions to the most challenging problems in clinical medicine as our understanding of the reactive proteome deepens.

References

[1] Baillie TA. Targeted Covalent Inhibitors for Drug Discovery. Angew Chem Int Ed Engl. 2016;55(43):13408-13421.

[2] Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010;53(7):2719-2740.

[3] Singh J, Petter RC, Baillie TA, Whitty A. The resurgence of covalent drugs. Nat Rev Drug Discov. 2011;10(4):307-317.

[4] De Cesco S, Kurian J, Dufresne C, Mittermaier AK, Moitessier N. Covalent inhibitors design and evaluation: a practical guide. Eur J Med Chem. 2017;138:96-114.

[5] Bandyopadhyay A, Gao J. Targeting the "undruggable" proteome using covalent chemical probes. Curr Opin Chem Biol. 2016;34:110-116.

[6] Abeles RH, Maycock AL. Suicide enzyme inactivators. Acc Chem Res. 1976;9(9):313-319.

[7] Lonsdale R, Ward RA. Structure-based design of targeted covalent inhibitors. Chem Soc Rev. 2018;47(11):3816-3843.

[8] Kalgutkar AS, Dalvie DK. Drug discovery for targeted covalent inhibitors: an emerging drug design paradigm. Expert Opin Drug Discov. 2012;7(7):561-581.

[9] Gehringer M, Laufer SA. Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology. J Med Chem. 2019;62(12):5673-5724.

[10] Lagoutte R, Patouret R, Winssinger N. Covalent inhibitors: an opportunity for rational drug design. Eur J Med Chem. 2016;112:204-226.

[11] Serafimova IM, Pisarcio M, Maly DJ, Theilhabers J, Whitty A. Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles. Nat Chem Biol. 2012;8(5):471-476.

[12] Dong J, Krasnova L, Finn MG, Sharpless KB. Sulfur(VI) Fluoride Exchange (SuFEx): Another Good Reaction for Click Chemistry. Angew Chem Int Ed Engl. 2014;53(36):9430-9448.

[13] Narayanan A, Jones LH. Sulfonyl fluorides as privileged warheads in chemical biology. Chem Sci. 2015;6(5):2650-2659.

[14] Hacker SM, Backus KM, Lazear MR, Forli S, Correia BE, Cravatt BF. Global profiling of lysine and histidine reactivity in the human proteome. Nat Chem. 2017;9(12):1181-1190.

[15] Bradshaw JM, McFarland JM, Paavilainen VO, Bisconte A, Tam D, Phillistides A, et al. Prolonged and tunable residence time using reversible covalent kinase inhibitors. Nat Chem Biol. 2015;11(7):525-531.

[16] Krishnan S, Miller RM, Tian B, Mulligan MP, Todd MJ, Remy A, et al. Design of reversible, cysteine-targeted Michael acceptors guided by kinetic and computational analysis. J Am Chem Soc. 2014;136(36):12624-12630.

[17] Copeland RA. The drug-target residence time model: a 10-year retrospective. Nat Rev Drug Discov. 2016;15(2):87-95.

[18] Strelow JM. A perspective on the kinetics of covalent binding. SLAS Discov. 2017;22(1):5-20.

[19] Schwartz PA, Kuzmic P, Solowiej J, Bergqvist S, Bolen B, Cai C, et al. Covalent kinase inhibitors: correlation of binding kinetics, thermodynamics, and efficacy. Proc Natl Acad Sci U S A. 2014;111(1):173-178.

[20] Barf T, Kaptein A. Irreversible protein kinase inhibitors: balancing the benefits and risks. J Med Chem. 2012;55(14):6243-6262.

[21] Bauer RA. Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies. Drug Discov Today. 2015;20(9):1061-1073.

[22] Tonge PJ. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov. 2018;17(1):1-20.

[23] Kathman SG, Statsyuk AV. Covalent tethering of fragments to lysine residues on protein surfaces. J Med Chem. 2016;59(8):3563-3569.

[24] London N, Miller RM, Krishnan S, Uchida K, Irwin JJ, Eidam O, et al. Covalent docking of large libraries for the discovery of chemical probes. Nat Chem Biol. 2014;10(12):1066-1072.

[25] Mortenson DE, Brighty GJ, Plate L, Bare G, Chen W, Li S, et al. "Inverse drug discovery" strategy to identify proteins that are targeted by electrophiles. J Am Chem Soc. 2018;140(1):200-210.

[26] Anscombe E, Meschini E, Mora-Vidal R, Martin-Martin P, Ramos D, Deepankumar S, et al. Identification and functional characterization of cellular targets for lysine-reactive vinyl sulfones. ACS Chem Biol. 2015;10(11):2470-2477.

[27] Chen W, Dong J, Plate L, Mortenson DE, Brighty GJ, Li S, et al. Tyrosine-Specific Chemical Modification with Sulfur(VI) Fluoride Exchange. J Am Chem Soc. 2016;138(23):7353-7364.

[28] Zhang T, Inguva A, Jones LH. Covalent targeting of non-cysteine residues in proteins. Chem Sci. 2022;13(4):1055-1073.

[29] McCormick F. K-Ras protein as a drug target. J Mol Med (Berl). 2016;94(3):253-258.

[30] Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217-223.

[31] Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503(7477):548-551.

[32] Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286-2294.

[33] Crawford JJ, Johnson AR, Misner DL, Belmont LD, Castanedo G, Choy JW, et al. Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. J Med Chem. 2018;61(6):2227-2245.

[34] Stepan AF, Walker DP, Bauman J, Price DA, Baillie TA, Kalgutkar AS, et al. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the metabolism and toxicity of thiophene-containing drugs. Chem Res Toxicol. 2011;24(9):1345-1410.

[35] Kalgutkar AS. Designing around structural alerts in drug discovery. J Med Chem. 2020;63(12):6276-6302.

[36] Meanwell NA. Toxicophores: groups and metabolic routes associated with liabilities in drug discovery. Chem Res Toxicol. 2016;29(4):564-616.

[37] Bradshaw JM. Reversible covalent bond formation in drug discovery. Future Med Chem. 2016;8(13):1585-1598.